Abstract
BackgroundBiosimilars, often priced at a discounted rate of originator biologics, may prompt switching patients from originator biologics to biosimilars for non-medical reasons. However, other relevant costs (e.g., non-medical switching (NMS)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have